Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

Inclusion Criteria Informed subject consent will be obtained from those patients meeting the following inclusion criteria: * Male and female patients 18 years or older. * Clinical and/or histopathological diagnosis of PRP * Candidate for systemic therapy (PASI ≥ 10) * Body surface area of involvement ≥ 10% * Good general health as confirmed by medical history * Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and * Patients who read and sign an approved informed consent for this study Exclusion Criteria Patients are to be excluded based on the following criteria: * Vulnerable study population * Pregnant or nursing women * Women planning a pregnancy within the study period * Human immunodeficiency virus (HIV) positivity * Known history of adverse reaction to Cosentyx * Known history of hepatitis B, hepatitis C, or tuberculosis * Personal or family history of inflammatory bowel disease